Please ensure Javascript is enabled for purposes of website accessibility

Why New Age Beverages Popped Over 21% This Morning

By Daniel Miller – Sep 24, 2019 at 11:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what investors need to know about New Age's announcement Tuesday, and where the company goes from here.

What happened

Shares of New Age Beverages Corporation (NBEV -1.96%), a producer of alternative beverages for more health-conscious consumers, with products ranging from tea and kombucha to cannabidiol (CBD) drinks, rose over 21% Tuesday morning after a big announcement. The Japanese Narcotics Control Division and the Japanese Ministry of Health have approved New Age's CBD products for sale in Japan. 

So what

The company announced the big approval as well as its intention to enter the market immediately. It's clearly a big win for the company, but many might not realize New Age is the first major company to gain approval to sell a portfolio of CBD products in the country.

A handful of CBD products on a table

New Age's lineup of Japanese CBD products. Image source: New Age Beverages.

"New Age is proud to introduce our lineup of CBD products to Japanese consumers and to be first with CBD in Japan. We believe we have one of the highest quality CBD portfolios worldwide and have leveraged all of our scientific insights and research and development expertise to develop these superior performing and highly efficacious products," Fumiyuki Isami, senior director in Japan for New Age, said in a press release.

Now what

New Age's business over the next decade will depend in large part on how popular CBD beverages become, and also on how difficult the regulatory process is for the category. New Age becoming the first major company with a full portfolio of products allowed in Japan is a serious victory and should give investors confidence it can secure approvals from other governments -- most importantly the U.S. government. Management has previously noted commitments from retailers that are in limbo pending FDA approval. While Japan's approval is a victory for New Age, and today's pop in stock price warranted, the two big questions are whether CBD beverages will be more than a brief fad and whether the FDA will make the regulatory environment in the U.S. more favorable to companies like New Age than it is right now.

Daniel Miller has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NewAge, Inc. Stock Quote
NewAge, Inc.
NBEV
$0.01 (-1.96%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.